 Objective antitumor activity acivicin patients recurrent CNS malignancies Southwest Oncology Group trial Acivicin glutamine antagonist dose-limiting schedule-dependent CNS toxicity predictable CSF penetration intravenous administration properties trial CNS malignancies Thirty-two patients recurrent residual malignant astrocytomas majority patients multiforme prior nitrosoureas median age years Southwest Oncology Group SWOG performance status major determinant response radiologic criteria tomographic CT and/or magnetic resonance imaging MRI tumor mass perpendicular planes cross-sectional area Standard solid tumor criteria response patients stable dose corticosteroids stable improved performance status neurologic examination objective responses complete remission years partial remissions days patients improvement disease requirements partial remission Toxicity mild nausea vomiting patients study due neurotoxicity depression hallucinations strict response criteria trial active agents carmustine BCNU objective antitumor activity malignant astrocytomas warrants study